Physician profile
Stuart Stark
NPI 1508836578
$72,838.37
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $18K · 2022: $35.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28,545.02 | 2019-2020 | |
| Lilly USA, LLC | $23,408.68 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $9,161.26 | 2019-2020 | |
| Allergan, INC. | $5,645.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $3,843.35 | 2019 | |
| Supernus Pharmaceuticals, INC. | $893.34 | 2019-2020 | |
| Bausch Health US, LLC | $751.95 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $266.27 | 2019 | |
| Upsher-Smith Laboratories LLC | $78.60 | 2019-2020 | |
| Promius Pharma LLC | $61.75 | 2019 | |
| Neurocrine Biosciences, INC. | $35.44 | 2022 | |
| Emd Serono, INC. | $34.56 | 2019-2020 | |
| Genzyme Corporation | $24.19 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.93 | 2019 | |
| Dermira, INC. | $20.44 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $15.26 | 2019 | |
| Ucb, INC. | $14.54 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.90 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.